每月一次长效帕瑞肽（SOM230C）治疗复发性或进展性脑膜瘤的II期研究。 - Suppr

Suppr

超能文献

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

作者信息

Chamberlain Marc C

出版信息

Neurology. 2015 Sep 22;85(12):1090. doi: 10.1212/WNL.0000000000001988.

DOI:10.1212/WNL.0000000000001988

PMID:26391415

Abstract

摘要

相似文献

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Neurology. 2015 Sep 22;85(12):1090. doi: 10.1212/WNL.0000000000001988.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Neurology. 2015 Jan 20;84(3):280-6. doi: 10.1212/WNL.0000000000001153. Epub 2014 Dec 19.

Comment: Medical therapy for recurrent or progressive meningiomas remains elusive.

Neurology. 2015 Jan 20;84(3):285. doi: 10.1212/WNL.0000000000001170. Epub 2014 Dec 19.

Author response.

Neurology. 2015 Sep 22;85(12):1090.

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

Neuro Oncol. 2011 May;13(5):530-5. doi: 10.1093/neuonc/nor044.

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.

Neurology. 2007 Sep 4;69(10):969-73. doi: 10.1212/01.wnl.0000271382.62776.b7.

Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy.

Neurochirurgie. 2021 Apr;67(2):193-197. doi: 10.1016/j.neuchi.2020.10.002. Epub 2020 Oct 22.

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.

Cancer Chemother Pharmacol. 2014 May;73(5):919-23. doi: 10.1007/s00280-014-2422-z. Epub 2014 Mar 12.

Successful mifepristone treatment of recurrent, inoperable meningioma.

Lancet. 1990 Jul 14;336(8707):124-5. doi: 10.1016/0140-6736(90)91647-s.

Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer.

World Neurosurg. 2016 Jul;91:670.e1-6. doi: 10.1016/j.wneu.2016.03.076. Epub 2016 Mar 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

作者信息

Chamberlain Marc C

出版信息

Neurology. 2015 Sep 22;85(12):1090. doi: 10.1212/WNL.0000000000001988.

DOI:10.1212/WNL.0000000000001988

PMID:26391415

Abstract

摘要

相似文献

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Neurology. 2015 Sep 22;85(12):1090. doi: 10.1212/WNL.0000000000001988.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Neurology. 2015 Jan 20;84(3):280-6. doi: 10.1212/WNL.0000000000001153. Epub 2014 Dec 19.

Comment: Medical therapy for recurrent or progressive meningiomas remains elusive.

Neurology. 2015 Jan 20;84(3):285. doi: 10.1212/WNL.0000000000001170. Epub 2014 Dec 19.

Author response.

Neurology. 2015 Sep 22;85(12):1090.

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

Neuro Oncol. 2011 May;13(5):530-5. doi: 10.1093/neuonc/nor044.

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.

Neurology. 2007 Sep 4;69(10):969-73. doi: 10.1212/01.wnl.0000271382.62776.b7.

Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy.

Neurochirurgie. 2021 Apr;67(2):193-197. doi: 10.1016/j.neuchi.2020.10.002. Epub 2020 Oct 22.

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.

Cancer Chemother Pharmacol. 2014 May;73(5):919-23. doi: 10.1007/s00280-014-2422-z. Epub 2014 Mar 12.

Successful mifepristone treatment of recurrent, inoperable meningioma.

Lancet. 1990 Jul 14;336(8707):124-5. doi: 10.1016/0140-6736(90)91647-s.

Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer.

World Neurosurg. 2016 Jul;91:670.e1-6. doi: 10.1016/j.wneu.2016.03.076. Epub 2016 Mar 30.